Italy Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Italy recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Italy recombinant protein therapeutics cdmo market highlights
- The Italy recombinant protein therapeutics cdmo market generated a revenue of USD 709.8 million in 2023 and is expected to reach USD 1,853.2 million by 2030.
- The Italy market is expected to grow at a CAGR of 14.7% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 709.8 million |
| Market revenue in 2030 | USD 1,853.2 million |
| Growth rate | 14.7% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Italy accounted for 3.4% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 2,892.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.43% in 2023. Horizon Databook has segmented the Italy recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The contract manufacturing sector is a major driver of the Italian economy. In Italy, most CDMOs operate exclusively in contract development & manufacturing. In addition, some are local multinationals with factories in Italy and abroad, with a large organizational structure & vast technical expertise. The increasing demand for treatment of various diseases, including cancer and rare genetic disorders, further drives the demand for CDMOs capable of producing patient-specific therapies.
This has led to the development of new & innovative medicines, fueling the Italian pharmaceutical industry. Biotechnology companies in Italy are focusing on oncology and various other diseases, including infectious diseases and inflammatory diseases. The recent reemergence of infectious diseases, such as COVID-19, has increased investments in developing new treatments. Such actions are likely to boost the market in Italy.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Italy Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
